Sign inJoin waitlistJoin the waitlist

TY

Teresa York

Associate Professor of Pediatrics and Division Head · Univ of Maryland Sch of Med

Credentials: · · ·

History

Pediatrics and Division Head · Univ of Maryland Sch of Med
Present
Univ of Maryland Sch of Med
Present
Univ of Maryland Sch of Med
Present

Pediatric Hematology Oncology
Medical University of South Carolina College of Medicine
2003–2006
Pediatrics
University of Maryland Program
2000–2003
West Virginia University Children’s Hospital
1997–2000
West Virginia University School of Medicine
1993–1997

Research

Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy
Blood · 2000 · 171 citations
Diagnosis of biphenotypic acute leukemia: a paradigmatic approach
International Journal of Clinical and Experimental Pathology · 2009 · 13 citations
Molecular basis for decreased folylpoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line
Leukemia Research · 2007 · 13 citations

AM
Ashley Munchel
2 papers
IG
Ivana Gojo
2 papers
Maria Baer
2 papers
Regina Macatangay
2 papers
XZ
Xianfeng Zhao
2 papers
AP
Abhinav Parikh
1 paper · 1 as a fellow
Bakri Alzarka
1 paper
Christa Nelson
1 paper
Elizabeth Montgomery
1 paper
HC
Helena Crowley
1 paper
HB
Henna Butt
1 paper · 1 as a resident
HD
Holly Deluca
1 paper

Clinical trials

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Site PI · Recruiting
Children's Oncology Group
2023–2028
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031